SYNACT — SynAct Pharma AB Cashflow Statement
0.000.00%
- SEK874.89m
- SEK815.57m
Annual cashflow statement for SynAct Pharma AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -31.3 | -76.7 | -106 | -224 | -90 |
Depreciation | |||||
Non-Cash Items | — | 0.088 | -0.306 | 10.2 | 10.2 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -1.95 | 11.6 | -12.6 | 38.8 | -10 |
Change in Accounts Receivable | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -33.2 | -65 | -118 | -100 | -89.2 |
Other Investing Cash Flow Items | -0.093 | -0.006 | 0.027 | 0.37 | 0 |
Sale/Maturity of Investment | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | -0.093 | -0.006 | 0.027 | 0.37 | 0 |
Financing Cash Flow Items | -5.04 | -5.6 | -27.3 | -4.75 | -6.14 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 44.7 | 74.3 | 201 | 54 | 87.4 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 11 | 9.45 | 84.2 | -45.9 | -1.19 |